Document Detail


Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer.
MedLine Citation:
PMID:  17149754     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Recently, it was shown that an inflammation-based prognostic score, the Glasgow Prognostic Score (GPS), provides additional prognostic information in patients with advanced cancer. The objective of the current study was to examine the value of the GPS compared with established scoring systems in predicting cancer-specific survival in patients with metastatic renal cancer. METHODS: One hundred nineteen patients who underwent immunotherapy for metastatic renal cancer were recruited. The Memorial Sloan-Kettering Cancer Center (MSKCC) score and the Metastatic Renal Carcinoma Comprehensive Prognostic System (MRCCPS) score were calculated as described previously. Patients who had both an elevated C-reactive protein level (>10 mg/L) and hypoalbuminemia (<35 g/L) were allocated a GPS of 2. Patients who had only 1 of those 2 biochemical abnormalities were allocated a GPS of 1. Patients who had neither abnormality were allocated a GPS of 0. RESULTS: On multivariate analysis of significant individual factors, only calcium (hazard ratio [HR], 3.21; 95% confidence interval [95% CI], 1.51-6.83; P = .002), white cell count (HR, 1.66; 95% CI, 1.17-2.35; P = .004), albumin (HR, 2.63; 95% CI, 1.38-5.03; P = .003), and C-reactive protein (HR, 2.85; 95% CI; 1.49-5.45; P = .002) were associated independently with cancer-specific survival. On multivariate analysis of the different scoring systems, the MSKCC (HR, 1.88; 95% CI, 1.22-2.88; P = .004), the MRCCPS (HR, 1.42; 95% CI, 0.97-2.09; P = .071), and the GPS (HR, 2.35; 95% CI, 1.51-3.67; P < .001) were associated independently with cancer-specific survival. CONCLUSIONS: An inflammation-based prognostic score (GPS) predicted survival independent of established scoring systems in patients with metastatic renal cancer.
Authors:
Sara Ramsey; Gavin W A Lamb; Michael Aitchison; John Graham; Donald C McMillan
Related Documents :
19585544 - Neurological mortality among u.s. veterans of the persian gulf war: 13-year follow-up.
18757324 - Impact of body mass index and weight change after treatment on cancer recurrence and su...
12115364 - Psychic vulnerability and the associated risk for cancer.
20007304 - Adherence to a mediterranean diet and risk of gastric adenocarcinoma within the europea...
21739434 - Investigation of phosphoprotein signatures of archived prostate cancer tissue specimens...
20016974 - Phylogeographic analysis of human papillomavirus 58.
Publication Detail:
Type:  Evaluation Studies; Journal Article    
Journal Detail:
Title:  Cancer     Volume:  109     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-01-17     Completed Date:  2007-02-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  205-12     Citation Subset:  AIM; IM    
Affiliation:
Department of Urology, Gartnavel General Hospital, Glasgow, United Kingdom. sara_l_ramsey@ntlworld.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
C-Reactive Protein / analysis
Carcinoma, Renal Cell / blood,  diagnosis*,  therapy
Female
Humans
Inflammation / blood,  diagnosis*
Kidney Neoplasms / blood,  diagnosis*,  therapy
Male
Middle Aged
Multivariate Analysis
Neoplasm Metastasis
Predictive Value of Tests
Prognosis
Serum Albumin / analysis
Survival Analysis
Chemical
Reg. No./Substance:
0/Serum Albumin; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, para...
Next Document:  Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irr...